Distinct pharmacologic substrate in lidocaine-sensitive, repetitive atrial tachycardia

Pablo A Chiale1, Luciano Faivelis, Hugo A Garro

  • 1Centro de Arritmias Cardíacas, Goverment of Buenos Aires City, Buenos Aires, Argentina. pablochiale@fibertel.com.ar

Insights

Lidocaine effectively treats repetitive atrial tachycardia. Adenosine and verapamil show varied responses, suggesting diverse electrophysiologic substrates and a role for delayed afterdepolarizations in this uncommon arrhythmia.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Pharmacology

Background:

  • Repetitive atrial tachycardia (RAT) is an uncommon arrhythmia with an unknown electrophysiologic substrate.
  • Pharmacologic responses of RAT have not been fully explored.

Purpose of the Study:

  • To investigate the effects of intravenous adenosine and verapamil in patients with lidocaine-sensitive atrial tachycardia.
  • To explore potential underlying electrophysiologic mechanisms of RAT.

Main Methods:

  • Sequential administration of intravenous adenosine (12 mg), lidocaine (1 mg/kg), and verapamil (10 mg) in 9 patients with RAT.
  • Simultaneous 12-lead electrocardiogram (ECG) monitoring and analysis of arrhythmia characteristics post-drug administration.
  • Radiofrequency ablation was performed in 5 patients.

Main Results:

  • Lidocaine abolished RAT in all 9 patients within 2 minutes.
  • Adenosine suppressed RAT in 2 patients; verapamil was effective in 2 patients.
  • Radiofrequency ablation successfully abolished the arrhythmia in 5 patients.

Conclusions:

  • Lidocaine-sensitive RAT can be suppressed by adenosine and/or verapamil, indicating diverse electrophysiologic substrates.
  • Delayed afterdepolarizations may play a significant role in the pathogenesis of some RAT cases.
  • Further research is needed to fully elucidate the mechanisms of RAT.

Related Concept Videos

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
Depolarizing Blockers: Mechanism of Action01:28

Depolarizing Blockers: Mechanism of Action

Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because succinylcholine...